Preclinical drug compounds targeting the melanocortin 3 receptor (MC3R) to regulate food intake and treat eating disorders such as anorexia nervosa.

Drug candidates targeting the melanocortin 4 receptor (MC4R) to treat genetic forms of obesity, including MC4R haploinsufficiency, where no FDA-approved drugs currently exist.